Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Li Zhang, Jing Zheng et al.|Journal of Thoracic Oncology|2021Cited by 44
Abstract 2997: Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK+ NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trialYunpeng Yang, Li Zhang, Jie Huang et al.|Cancer Research|2020Cited by 4